{"id":"benaglutide-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benaglutide mimics glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon release from alpha cells. This mechanism helps lower blood glucose levels in patients with type 2 diabetes. The drug also slows gastric emptying and promotes satiety, contributing to improved glycemic control.","oneSentence":"Benaglutide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:28:17.958Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06775093","phase":"NA","title":"Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-03-01","conditions":"Polycystic Ovary Syndrome, Obesity, Infertility, Female","enrollment":392},{"nctId":"NCT05226000","phase":"PHASE1","title":"Pharmacokinetics of Benaglutide Injection in Overweight/Obese Adults","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2020-07-07","conditions":"Overweight/Obese Adults","enrollment":16},{"nctId":"NCT03986008","phase":"PHASE3","title":"Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2019-12-01","conditions":"Obesity","enrollment":60},{"nctId":"NCT03593668","phase":"PHASE4","title":"Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2017-12-30","conditions":"Obesity; Drug","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Benaglutide Injection","rhGLP-1(7-36)"],"phase":"marketed","status":"active","brandName":"Benaglutide Injection","genericName":"Benaglutide Injection","companyName":"The Affiliated Hospital of Qingdao University","companyId":"the-affiliated-hospital-of-qingdao-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benaglutide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}